ÌÇÐÄÆƽâ°æ

Share of EBITDA margin of Aurobindo Pharma Limited in India from financial year 2013 to 2024

© ÌÇÐÄÆƽâ°æ 2026
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

August 2024

Region

India

Survey time period

FY 2013 to FY 2024

Supplementary notes

India's financial year begins in April and ends in March. For example, FY 2024 started in April 2023 and ended in March 2024.

Values have been rounded for clarity.

Citation formats

Aurobindo Pharma's EBITDA margin FY 2013-2024

Published by A. Minhas, Oct 17, 2024

In fiscal year 2024, Aurobindo Pharma's EBITDA margin was around ** percent, indicating an increase compared to the previous fiscal year. The Indian company's EBITDA was valued at over ** billion Indian rupees in fiscal year 2024.

Log in or register to access precise data.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Statistics on

About the industry

10

About the region

10

Selected statistics

10

Other regions

10

Related statistics

10

Further Content: You might find this interesting as well

Topics

Merck & Co.Global pharmaceutical industryPharmaceutical industry in the U.S.Top pharmaceutical drugsPfizer
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.